Company Quick10K Filing
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 -0 $-0
20-F 2019-03-28 Annual: 2018-12-31
20-F 2018-03-29 Annual: 2017-12-31

Inflarx Financials

IFRX Metrics, Comps, Filings

Annual | Quarterly


We are a clinical-stage biopharmaceutical company focused on applying our proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Our lead product candidate, IFX-1, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. We are developing IFX-1 for the treatment of Hidradenitis Suppurativa, or HS, a rare and chronic debilitating systemic inflammatory skin disease, for which we completed enrollment into a Phase IIb clinical trial in the fourth quarter of 2018. Beyond HS, we intend to develop IFX-1 and other proprietary antibodies to address a wide array of complement-mediated diseases with significant unmet medical needs, including ANCA-associated vasculitis, or AAV, a rare and life-threatening autoimmune disease and Pyoderma Gangrenosum, a chronic inflammatory skin disorder, and potentially other new indications.

In connection with our initial public offering in the fourth quarter of 2017, InflaRx executed a corporate reorganization whereby InflaRx N.V. became the holding company for InflaRx GmbH, which remains the principal operating subsidiary of InflaRx N.V. In the initial step of the corporate reorganization, the existing preferred and common shareholders of InflaRx GmbH each became a party to a notarial deed of issue pursuant to which they subscribed for new common shares of Fireman B.V., a newly incorporated Dutch private company with limited liability, and agreed to contribute and transfer their shares in InflaRx GmbH to Fireman B.V. in consideration therefor. Upon consummation of the contribution and transfer, Fireman B.V. became the sole shareholder of InflaRx GmbH. In the final step of the corporate reorganization, the legal form of Fireman B.V. was converted from a Dutch private company with limited liability to a Dutch public company with limited liability. The conversion resulted in a name change from Fireman B.V. to InflaRx N.V.

The SEC maintains an Internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is Our website can be found at The information on our website is not incorporated by reference into this Annual Report, and you should not consider information contained on our website to be a part of this Annual Report.

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Imagistics (IGI)
Bain Capital Specialty Finance (BCSF)
Pelican Financial (PFI)
Storage Technology (STK)
Pet DRx (VETS)
GSV Capital (GSVC)
Oxford Square Capital (OXSQ)
Firsthand Technology Value Fund (SVVC)
Source Capital (SOR)
Gladstone Investment (GAIN)
BlackRock TCP Capital (TCPC)
CM Finance (CMFN)
Investcorp Credit Management BDC (CMFNL)
Prospect Capital (PSEC)
Inflarx (IFRX) 0% 159,214 7,824 0 0 0 0 -0
Futures Portfolio Fund (FPF) -3.5 6% 270,766 5,707 0 0 17,343 17,343 -60,572
GS Acquisition Holdings (GSAH) -59.0 1% 705,562 25,385 0 0 9,915 11,927 -704,115
Delphi Financial Group (DFP) 0% -0.0 2% 8,634,408 6,854,525 1,925,794 0 183,130 273,379 -0
Greif (GEF) 21% 5.7 4% 5,426,700 4,214,300 4,595,000 959,900 194,200 471,000 2,679,000
Neiman Marcus (NMS) 7% 10.9 -2% 7,359,000 6,981,939 4,688,651 315,500 -163,660 453,767 4,943,355

Balance Sheet ($'000)2017-12-312018-12-31
Accounts Receivable
Accounts Payable
Long-Term Debt
Stockholders' Equity
Income Statement ($'000)2017-12-312018-12-31
Cost of Revenue
Gross Profit-37,815
Net Income-24,238-29,815
Cash Flow ($'000)2017-12-312018-12-31
Cash Operating
Cash Investing
Cash Financing